Trump impeachment inquiry could put healthcare deals on back burner

As House Democrats launch a formal impeachment inquiry against President Trump, bipartisan healthcare efforts focused on lowering drug prices and healthcare costs are at risk of falling by the wayside, The Hill reported.

The impeachment process could put a halt to some of the bipartisan talks between Republicans and Democrats, particularly surrounding surprise billing and high drug prices, where some common ground has been found.

House Speaker Nancy Pelosi (D-CA) recently introduced a bill aimed at lowering drug prices, while the Trump administration has taken several steps to lower drug prices or reform healthcare prices by mandating more transparency. However, healthcare may not be the only critical legislative issue placed on the backburner, according to The Hill.

With an impeachment inquiry marching ahead, Democrats are still working on healthcare proposals––for now. Pelosi’s bill was reviewed by the House Energy and Commerce Committee Sept. 25, The Hill noted. During previous impeachment inquiries in other administrations, agendas still moved forward.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.